Vor Biopharma (VOR) Other Gross PP&E Adjustments (2020 - 2026)
Vor Biopharma (VOR) reported Other Gross PP&E Adjustments of -$3.2 million for Q1 2026, up 80.29% year-over-year from -$1.8 million in Q1 2025, and up 14.16% on a QoQ basis from -$3.7 million in Q4 2025.
Vor Biopharma (VOR) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$3.2 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 80.29% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.2 million (up 80.29% YoY) and the FY2025 annual result came in at -$3.7 million, up 80.24% from the prior year.
- Other Gross PP&E Adjustments grew to -$3.2 million in Q1 2026 per VOR's latest filing, from -$3.7 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$1.6 million in Q2 2025 and bottomed at -$29.9 million in Q3 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$20.2 million (2024), against an average of -$18.2 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments tumbled 286.58%; it then surged 91.87% in 2025.
- Tracing VOR's Other Gross PP&E Adjustments over 5 years: stood at -$28.9 million in 2022, then grew by 18.85% to -$23.5 million in 2023, then advanced by 19.22% to -$18.9 million in 2024, then surged by 80.24% to -$3.7 million in 2025, then gained by 14.16% to -$3.2 million in 2026.
- Per Business Quant, the three latest VOR Other Gross PP&E Adjustments figures stand at -$3.2 million (Q1 2026), -$3.7 million (Q4 2025), and -$4.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Vor Biopharma | 628.83 Mn | 628.83 Mn | - | -3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.21 Mn |
| Mar 31, 2026 | -3.21 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Sep 30, 2025 | -4.38 Mn |
| Sep 30, 2025 | -4.38 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Mar 31, 2025 | -16.31 Mn |
| Mar 31, 2025 | -16.31 Mn |
| Dec 31, 2024 | -18.95 Mn |
| Dec 31, 2024 | -18.95 Mn |
| Sep 30, 2024 | -19.40 Mn |
| Sep 30, 2024 | -19.40 Mn |
| Jun 30, 2024 | -20.16 Mn |
| Jun 30, 2024 | -20.16 Mn |
| Mar 31, 2024 | -21.81 Mn |
| Mar 31, 2024 | -21.81 Mn |
| Dec 31, 2023 | -23.45 Mn |
| Dec 31, 2023 | -23.45 Mn |
| Sep 30, 2023 | -24.80 Mn |
| Sep 30, 2023 | -24.80 Mn |
| Jun 30, 2023 | -26.01 Mn |
| Jun 30, 2023 | -26.01 Mn |
| Mar 31, 2023 | -27.73 Mn |
| Mar 31, 2023 | -27.73 Mn |
| Dec 31, 2022 | -28.90 Mn |
| Dec 31, 2022 | -28.90 Mn |
| Sep 30, 2022 | -29.85 Mn |
| Sep 30, 2022 | -29.85 Mn |
| Jun 30, 2022 | -29.55 Mn |
| Jun 30, 2022 | -29.55 Mn |
| Mar 31, 2022 | -9.31 Mn |
| Mar 31, 2022 | -9.31 Mn |
| Dec 31, 2021 | -7.48 Mn |
| Dec 31, 2021 | -7.48 Mn |
| Sep 30, 2021 | -9.12 Mn |
| Sep 30, 2021 | -9.12 Mn |
| Jun 30, 2021 | -9.69 Mn |
| Jun 30, 2021 | -9.69 Mn |
| Mar 31, 2021 | -11.02 Mn |
| Mar 31, 2021 | -11.02 Mn |
| Dec 31, 2020 | -12.76 Mn |
| Dec 31, 2020 | -12.76 Mn |